[go: up one dir, main page]

WO2011072141A1 - Compositions et procédés pour le traitement de la dégénérescence maculaire - Google Patents

Compositions et procédés pour le traitement de la dégénérescence maculaire Download PDF

Info

Publication number
WO2011072141A1
WO2011072141A1 PCT/US2010/059719 US2010059719W WO2011072141A1 WO 2011072141 A1 WO2011072141 A1 WO 2011072141A1 US 2010059719 W US2010059719 W US 2010059719W WO 2011072141 A1 WO2011072141 A1 WO 2011072141A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cyclodextrin
macular degeneration
compounds
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/059719
Other languages
English (en)
Inventor
Thomas A. Jordan
John Clifford Chabala
Gerald D. Cagle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aldeyra Therapeutics Inc
Original Assignee
Neuron Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Systems Inc filed Critical Neuron Systems Inc
Priority to CA2782015A priority Critical patent/CA2782015C/fr
Priority to JP2012543284A priority patent/JP5885670B2/ja
Priority to US13/514,769 priority patent/US9814701B2/en
Publication of WO2011072141A1 publication Critical patent/WO2011072141A1/fr
Anticipated expiration legal-status Critical
Priority to US15/782,470 priority patent/US20180092882A1/en
Priority to US18/241,598 priority patent/US12097188B2/en
Priority to US18/786,975 priority patent/US20250144080A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • Macular degeneration is a leading cause of progressive blindness.
  • the macula is the central region of the retina and contains the fovea where high acuity central vision is processed.
  • Macular degeneration is a neurodegenerative disease in the macula that progressively causes disabling deficits in visual function.
  • Age-related macular degeneration is the most common form and first appears at middle age or later.
  • AMD age-related macular degeneration
  • FAF fundus auto-fluorescence
  • RPE retinal pigment epithelial
  • A2E is a reaction product of all- trans retinaldehyde (RAL) and phosphatidylethanolamine (PE), a membrane phospholipid found in the disc membranes of photoreceptor outer segments.
  • the RAL that reacts with PE escapes from the visual cycle (step 3b in Figure 1), a metabolic pathway in the back of the eye that (i) converts vitamin A from an alcohol (retinol) to a photo-reactive aldehyde (1 ⁇ -cis- retinaldehyde) for use in photo-transduction by opsin proteins in photoreceptor cell outer segments, and (ii) converts RAL to retinol after photo-transduction.
  • retinol an alcohol
  • a photo-reactive aldehyde (1 ⁇ -cis- retinaldehyde
  • RAL converts RAL to retinol after photo-transduction.
  • A2E precursors form reversibly in photoreceptor outer segments, which are ingested by neighboring RPE cells after diurnal shedding.
  • A2E The final and irreversible step in the biosynthesis of A2E takes place in the acidic environment of RPE cell lysosomes.
  • A2E accumulates in RPE cells, it gradually poisons them by multiple cytotoxic mechanisms including lysosomal failure. This leads to the accumulation of undigested cellular debris called lipofuscin, which contains A2E and can be detected clinically by FAF.
  • lipofuscin As RPE cells deteriorate, they lose their ability to participate in the visual cycle and are unable to provide photoreceptors with other metabolic support required for normal retinal function (see Figure 1 ; Lamb TD, Pugh EN, Dark adaptation and the retinoid cycle of vision. Prog. Retinal and Eye Res. 2004;23 :307). As their metabolic support is withdrawn, photoreceptors fail to renew their shed outer segments and visual function is progressively lost. Reducing A2E formation will allow RPE cells to recover from A2E poisoning and resume their normal metabolic support of photoreceptor cells.
  • WO 2006/127945 discloses compounds and compositions that have been shown to reduce the formation of A2E, which as described above is the underlying etiology of macular degeneration including dry AMD and Stargardt's disease. These compounds are designed to inhibit A2E biosynthesis by reducing the amount of free RAL available for reaction with PE in photoreceptor outer segments, which is the first step in the A2E biosynthetic pathway. These compounds are lipophilic by design (i.e.
  • logP or clogP which are called logD or clogD respectively at pH 7.4 as used herein
  • logP or clogP which are called logD or clogD respectively at pH 7.4 as used herein
  • a different way to reduce A2E biosynthesis is to inhibit one or more proteins of the visual cycle, because when the visual cycle is inhibited, less RAL escapes the visual cycle and becomes available to react with PE and form A2E precursors.
  • Chronic treatment with a visual cycle inhibitor has been shown to reduce A2E synthesis in mouse (Radu et al, Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A. 2003; 100:4742).
  • neuroprotection mechanisms of action including but not limited to neurotrophic receptor agonists, anti-inflammatory compounds including complement cascade inhibitors, anti- apoptosis compounds, steroids and anti-oxidant compounds, and limiting the progression to wet AMD with VEGF receptor blockers which mitigate the effects of VEGF signaling by RPE cells that are in severe oxidative stress as a consequence of A2E toxicities.
  • topical ocular administration minimizes systemic exposure compared to oral dosing.
  • the present invention provides formulations and methods for topical ocular dosing of lipophilic compounds which treat macular degeneration (including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease) by reducing the formation of A2E and other naturally occurring bis-retinoids, by reacting covalently with free RAL that escapes the visual cycle and would otherwise form precursors of these compounds.
  • Figure 1 depicts the visual cycle.
  • Figure 2 depicts a time profile of the concentration of 14 C-Compound A in ng/g of ocular tissue.
  • Figure 3 depicts effects of RA treatment on dark adaptation rate in the mouse after acute TO or IP administration of 13-czs-retinoic acid.
  • One embodiment of the present invention provides pharmaceutical compositions for treating macular degeneration (including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease).
  • macular degeneration including dry AMD, GA secondary to dry AMD, wet AMD and Stargardt's disease.
  • the root cause of macular degeneration is the cytotoxic accumulation in RPE cells of naturally occurring bis-retinoids including A2E. This accumulation can be lowered pharmacologically by limiting the amount of free RAL that escapes the visual cycle and otherwise reacts with PE to form their precursors. As the accumulation of these compounds is reduced pharmacologically, RPE cells can recover from cytotoxic damage and resume their metabolic support of photoreceptors which is essential for normal visual function.
  • publications WO 2006/127945 compounds are described which reduce A2E accumulation in this manner and are therefore useful in treating macular degeneration.
  • the instant application incorporates by reference the subject matter of WO 2006/127945.
  • Lipophilic compounds which reduce A2E and thereby treat macular degeneration including dry AMD and Stargardt's disease by other means (e.g. by inhibiting the visual cycle) are also included within the scope of this invention.
  • Such compounds include ACU-4429. All such compounds have a logP or clogP greater than 0.
  • topical ocular administration minimizes systemic exposure compared to oral dosing.
  • most topical formulations have failed to deliver efficacious levels of drug to the retina which is the site of the mechanism of action.
  • a lipophilic active agent and a cyclodextrin, or chemically modified cyclodextrin including trimethyl- ⁇ - cyclodextrin, 2-hydroxyethyl-P-cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3- hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt)
  • efficacious levels of the lipophilic active agent are delivered to the back of the eye and specifically to the RPE and retina.
  • compositions of a lipophilic active agent and an oligomeric or a polymeric carrier such as a cyclodextrin or chemically modified cyclodextrin including trimethyl-P-cyclodextrin, 2-hydroxyethyl-p-cyclodextrin, 2- hydroxypropyl-P-cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt) are useful for the treatment of macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease).
  • macular degeneration including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease.
  • One exemplification of the present invention is represented by a topical ophthalmic composition containing an active lipophilic compound and an oligomeric or a polymeric carrier such as a cyclodextrin, or a chemically modified cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl- -cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3- hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt) in an aqueous solution or a gel dispersion.
  • an active lipophilic compound and an oligomeric or a polymeric carrier
  • an oligomeric or a polymeric carrier such as a cyclodextrin, or a chemically modified cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl- -cyclodextrin, 2-
  • Such active lipophilic compounds include those that reduce A2E by reacting covalently with RAL, e.g. the compounds of WO 2006/127945.
  • Illustrative of such compounds are those described in WO 2006/127945 the contents of which application are herein incorporated by reference.
  • Exemplifying the compounds which may be employed in the instant invention are the compounds of formula
  • X, Y, and Z are each, independently, N, CH, C with the NH 2 attached, or absent, such that one of X, Y, and Z is N; p is 0, 1, 2, or 3,
  • B is a halogen atom, hydroxyl, carbamoyl, amino, or aryl, A is s D is unbranched lower alkyl.
  • compound A of paragraph (00027) of WO 2006/ 127945 and pharmaceutically acceptable salts thereof may be employed in the instant invention.
  • L is a single bond or CH 2 ;
  • X, Y, and Z are each, independently, N, NH, O, S, CB, CH, or absent, such that one of X, Y, and Z is N or
  • the amount of active agent in the composition will vary dependent on the intrinsic activity of the compound. However, for compounds of formula la and formula Ilia the amount will generally be from 0.01-1.0% weight/volume and more particularly 0.1% to 0.5% weight/volume.
  • a compound as described above may be used or a pharmaceutically acceptable salt of said compound.
  • the term lipophilic compound is meant to include the compound and its pharmaceutically acceptable salts.
  • a pharmaceutically acceptable salt herein means a salt that is capable of being topically delivered to the eye of a patient.
  • the carrier in the composition is an oligomeric or a polymeric carrier such as a cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl ⁇ -cyclodextrin, 2- hydroxypropyl- -cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt).
  • a cyclodextrin including trimethyl-p-cyclodextrin, 2-hydroxyethyl ⁇ -cyclodextrin, 2- hydroxypropyl- -cyclodextrin, 3-hydroxypropyl-P-cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt).
  • ⁇ -cyclodextrin sulfobutylether sodium salt Exemplifying an oligomeric or a polymeric carrier is ⁇ -cyclod
  • the amount of ⁇ -cyclodextrin sulfobutylether sodium salt in the aqueous preparation may range from about 0.01% to 30% weight/volume. In one illustration the concentration of ⁇ -cyclodextrin sulfobutylether sodium salt is 5-25% weight/volume. Further illustrating the concentration of ⁇ -cyclodextrin sulfobutylether sodium salt is 9.5-20%) weight/volume. In one exemplification the concentration of ⁇ -cyclodextrin sulfobutylether is 9.5% weight/volume.
  • each lipophilic agent may be formulated with each of the excipients.
  • the composition may contain saline and be buffered with for example a phosphate buffer so that the pH of the composition is brought to a pH range of 5.5-8.5 or more particularly a pH of 6.5-7.5.
  • a preservative may optionally be included in the composition. Such preservatives can include both chemical stabilizers and antiseptics.
  • Compounds such as Compounds A are stable under the conditions of use, however other compounds may require the use of other excipients such as anti-oxidants.
  • a second embodiment of the invention is directed to a method of treating macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease), by administering a topical formulation of an active lipophilic compound and a carrier to the eye(s) of a patient.
  • macular degeneration including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease
  • the present invention provides a topical ophthalmic composition for use in treating macular degeneration wherein said composition comprises an active lipophilic compound and a carrier or a pharmaceutically acceptable salt thereof in an aqueous solution.
  • Exemplifying the carrier is ⁇ -cyclodextrin sulfobutylether or a pharmaceutically acceptable sat thereof.
  • the active lipophilic compound in each of these embodiments includes those that reduce A2E by reacting with RAL, e.g. the compounds of WO 2006/127945. Examples of such compounds are those described in WO 2006/127945. Exemplifying such compounds are Compounds A, B and C. Lipophilic Compounds which function by other mechanisms such as ACU-4429 are also included.
  • the term lipophilic compound is meant to include both the compound and its pharmaceutically acceptable salts.
  • the excipient in the formulation is oligomeric or polymeric such as a cyclodextrin or a chemically modified cyclodextrin, more particularly including ⁇ -cyclodextrin sulfobutylether sodium salt (or potassium salt).
  • each lipophilic compound formulated with each excipient.
  • the formulation may be buffered to a pH range of 5.5-8.5 or more particularly a pH of 6.5-7.5.
  • the buffer may be a phosphate buffer.
  • the formulation may be applied as an aqueous solution or a gel dispersion and the solution may be a saline solution. The accumulation of lipofuscin occurs in RPE cells in the back of the eye.
  • topical compositions as described herein deliver pharmacologically active levels of lipophilic active drug safely to the back of the eye after topical ocular administration and are therefore useful in the treatment of macular degeneration (including dry age-related macular degeneration, GA secondary to dry AMD, wet AMD and Stargardt's disease). Efficacious levels are defined as those that reduce A2E accumulation significantly in animal studies.
  • Formulations of a lipophilic active agent and an oligomeric or a polymeric carrier are prepared by stirring an aqueous suspension or solution of a polymeric carrier such as a cyclodextrin, or chemically modified cyclodextrin including trimethyl- -cyclodextrin, 2- hydroxyethyl- -cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, 3-hydroxypropyl-P- cyclodextrin, and ⁇ -cyclodextrin sulfobutylether sodium (or potassium) salt with water, saline or phosphate-buffered saline at a temperature from 20°C to 50°C, but preferably at ambient temperature, for 0.1 -24 hr, depending on the polymeric carrier.
  • a polymeric carrier such as a cyclodextrin, or chemically modified cyclodextrin including trimethyl- -cyclodextrin, 2- hydroxyethyl
  • the lipophilic active agent is added as a solid or neat liquid to the thus formed aqueous suspension or solution of polymeric carrier, and the resulting mixture is stirred at a temperature from 20°C to 50°C, but preferably at ambient temperature, for 0.1-24 hr, but typically from 0.5-2 hr, depending on the lipophilic active agent.
  • the thus formed formulation of a lipophilic active agent and an oligomeric or a polymeric carrier may then be treated with an aqueous solution of an inorganic or organic acid or an inorganic or organic base to adjust the pH of the solution as desired.
  • preservatives including both chemical stabilizers and antiseptics.
  • Example 1 Preparation of a 0.1% w/v aqueous formulation of Compound A with 9.5% w/v ⁇ -cyclodextrin sulfobutylether.
  • the preparation was carried out in a 1000 ml beaker equipped with a stirring bar for mixing. Approximately 60% of the targeted weight of sterile water was added to the beaker. Stirring was adjusted so as not to incorporate air. Anhydrous dibasic sodium phosphate (0.83% of the total batch weight) and sodium phosphate monobasic monohydrate (0.017% of the total batch weight) was added to the vessel and mixed until dissolved, ⁇ - cyclodextrin sulfobutylether (9.5% of the total batch weight) was slowly added to the beaker and the solution mixed until dissolved. Compound A (0.1% of the total batch weight) was slowly added and mixed until dissolved. A sample was extracted and the pH measured. If the pH was not in the range 7.3 ⁇ 0.05 , adjustment was made with IN aqueous NaOH or IN aqueous HC1. The batch weight was measured and the amount of sterile water needed to bring to final batch weight was determined and added.
  • the target tissue for the biological activity of compounds which reversibly react with RAL, e.g. Compounds A, B and C, is the outer segment of retinal photoreceptor cells.
  • TO topical optical
  • Compound A delivers therapeutically useful amounts of, for example, Compound A to the retina
  • C57BL/6 mice, the parent strain of abcr -I- mice (knockout mouse) were treated intraperitoneal ly (IP) with 14 C-Compound A at 10 mg/kg ("efficacious dose"), specifically a dose that when repeated daily for 56 days reduced A2E formation by 71% (p ⁇ 0.01) in the abcr -I- mouse.
  • the eyes of the mice were enucleated and the posterior eyecup was dissected, extracted and analyzed by liquid scintillation chromatography (LSC) for ,4 C-Compound A.
  • LSC liquid scintillation chromatography
  • PK pharmacokinetics
  • Compound A in four intraocular regions of Cynomolgus Macaques was measured after topical dosing of 40 ⁇ per eye of 0.50% weight/volume 1 C-Compound A in ⁇ -cyclodextrin sulfobutylether sodium salt in phosphate- buffered saline.
  • Sampling of intraocular regions (vitreous humor, retina+RPE, anterior eyecup, and posterior eyecup) and blood for PK evaluation was conducted at 0.25, 0.5, 1, 3, 6 and 9 hours post dose.
  • Figure 2 shows the time course of 14 C-Compound A concentration expressed in nanograms (ng ) per gram (g) of ocular tissue.
  • retinoids can be used to demonstrate that a small lipophilic compound in a composition containing ⁇ -cyclodextrin sulfobutylether sodium salt exhibits biological activity in the retina minutes to hours after topical application to the front of the eye.
  • a retinoid useful for this purpose is 13-m-retinoic acid (RA, also known as isotretinoin).
  • RA 13-m-retinoic acid
  • Mice treated IP at 20 mg/kg with RA show visual cycle inhibition ( Figure 3).
  • Independent studies demonstrate that the visual cycle inhibition decreases A2E synthesis (Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH.
  • Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci 2003;100:4742).
  • mice treated TO with one or two 30 eyedrops of a composition containing 0.2% weight/volume RA and 20% weight/volume ⁇ -cyclodextrin sulfobutylether sodium salt in phosphate-buffered saline showed a dose-responsive inhibition of DA similar to that observed after IP dosing ( Figure 3) ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des compositions ophtalmiques topiques d'un composé lipophile et d'un support oligomère ou polymère, les compositions étant utiles dans le traitement et la prévention de la dégénérescence maculaire. L'invention porte également sur des procédés de traitement de la dégénérescence maculaire à l'aide d'une composition ophtalmique topique d'un composé lipophile et d'un support oligomère ou polymère.
PCT/US2010/059719 2009-12-11 2010-12-09 Compositions et procédés pour le traitement de la dégénérescence maculaire Ceased WO2011072141A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2782015A CA2782015C (fr) 2009-12-11 2010-12-09 Compositions ophthalmiques topiques et methodes de traitement de la degenerescence maculaire
JP2012543284A JP5885670B2 (ja) 2009-12-11 2010-12-09 黄斑変性の処置のための組成物および方法
US13/514,769 US9814701B2 (en) 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration
US15/782,470 US20180092882A1 (en) 2009-12-11 2017-10-12 Compositions and methods for the treatment of macular degeneration
US18/241,598 US12097188B2 (en) 2009-12-11 2023-09-01 Compositions and methods for the treatment of macular degeneration
US18/786,975 US20250144080A1 (en) 2009-12-11 2024-07-29 Compositions and methods for the treatment of macular degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28574509P 2009-12-11 2009-12-11
US61/285,745 2009-12-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,769 A-371-Of-International US9814701B2 (en) 2009-12-11 2010-12-09 Compositions and methods for the treatment of macular degeneration
US15/782,470 Continuation US20180092882A1 (en) 2009-12-11 2017-10-12 Compositions and methods for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
WO2011072141A1 true WO2011072141A1 (fr) 2011-06-16

Family

ID=44145918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/059719 Ceased WO2011072141A1 (fr) 2009-12-11 2010-12-09 Compositions et procédés pour le traitement de la dégénérescence maculaire

Country Status (4)

Country Link
US (4) US9814701B2 (fr)
JP (4) JP5885670B2 (fr)
CA (1) CA2782015C (fr)
WO (1) WO2011072141A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116836A2 (fr) 2013-01-23 2014-07-31 Aldexa Therapeutics, Inc. Maladies liées à un aldéhyde toxique et traitement
US20150344447A1 (en) * 2013-01-25 2015-12-03 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
US9364471B2 (en) 2005-05-26 2016-06-14 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2017035077A1 (fr) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Composés deutérés et leurs utilisations
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10426790B2 (en) 2016-02-28 2019-10-01 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
EP3454858A4 (fr) * 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. Polythérapie de troubles et de maladies inflammatoires oculaires
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
EP3934660A1 (fr) 2019-03-05 2022-01-12 Cornell University Compositions de matière présentant une activité pour éliminer la lipofuscine de cellules rétiniennes
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2022092896A1 (fr) * 2020-10-29 2022-05-05 주식회사 피노바이오 Composition pharmaceutique destinée à être administrée comme collyre à un patient nécessitant une protection de nerf optique
JP2022526917A (ja) * 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2006127945A1 (fr) * 2005-05-26 2006-11-30 Neuron Systems Compositions et methodes de traitement de maladies retiniennes

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU8942491A (en) 1990-10-22 1992-05-20 Bausch & Lomb Incorporated Method and composition for cleaning contact lenses
CA2054339C (fr) 1990-11-02 2002-12-24 Francesco G. Salituro Derives du 3-amidoindolyl
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JPH08175985A (ja) 1994-12-26 1996-07-09 Lion Corp 点眼剤
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
JP2001508029A (ja) 1996-08-01 2001-06-19 ダウ・アグロサイエンス・エル・エル・シー 殺菌・殺カビ活性を有する４―置換キノリン誘導体
KR20000029843A (ko) 1996-08-06 2000-05-25 디. 제이. 우드;스피겔 알렌 제이 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체
JP2001524115A (ja) 1997-05-02 2001-11-27 シェリング アクチェンゲゼルシャフト 置換された複素環式化合物及び医薬におけるその使用
JPH10306022A (ja) 1997-05-06 1998-11-17 Lion Corp 点眼剤
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
HUP0102612A2 (hu) 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
CA2392085A1 (fr) 1999-11-15 2001-05-25 Smithkline Beecham Corporation Methane-sulfonate de carvedilol
WO2001041757A1 (fr) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Composition pharmaceutique contenant de la cyclodextrine
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001318350A (ja) 2000-05-11 2001-11-16 Lion Corp コンタクトレンズ用溶液
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
CA2416228C (fr) * 2002-01-15 2010-07-13 Olsonet Communications Corporation Noeuds de communication pour utilisation avec un reseau ad hoc de communication sans fil
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
EP3326623A1 (fr) 2003-03-14 2018-05-30 University of Washington Remplacements de rétinoïdes et agonistes de l'opsine et leurs procédés d'utilisation
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP1621199B8 (fr) 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedes a des affections, a usage ophtalmique
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
ES2426288T3 (es) 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
KR20060123208A (ko) 2003-10-27 2006-12-01 아스테라스 세이야쿠 가부시키가이샤 피라진 유도체 및 이의 약학적 용도
CA2546042A1 (fr) 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration de la degenerescence maculaire et d'autres maladies ophtalmiques
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
AU2005215778B2 (en) 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
WO2006002473A1 (fr) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Procédé de controle de dommages causés par des aldéhydes alpha, béta-insaturés
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
AU2005302608A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
JPWO2006077821A1 (ja) 2005-01-19 2008-06-19 大日本住友製薬株式会社 アルドステロン受容体調節剤としての芳香族スルホン化合物
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN1830964B (zh) 2005-03-11 2011-06-15 中国科学院上海药物研究所 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途
WO2006122183A2 (fr) 2005-05-10 2006-11-16 Cytophil, Inc. Hydrogels injectables et leurs procedes de fabrication et d'utilisation
TWI424838B (zh) 2005-12-27 2014-02-01 Lion Corp Composition of soft contact lens and method for inhibiting adsorption
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
WO2007118276A1 (fr) 2006-04-14 2007-10-25 Prana Biotechnology Ltd Procédé de traitement de la dégénérescence maculaire liée a l'âge (amd)
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
RU2009106461A (ru) 2006-07-25 2010-08-27 Энвиво Фармасьютикалз, Инк. (Us) Хинолиновые производные
JP2010500406A (ja) 2006-08-14 2010-01-07 シェーリング コーポレイション ５−（１（ｓ）−アミノ−２−ヒドロキシエチル）−ｎ−［（２，４−ジフルオロフェニル）−メチル］−２−［８−メトキシ−２−（トリフルオロメチル）−５−キノリン］−４−オキサゾールカルボキサミドの塩
EP2056792B1 (fr) 2006-08-31 2023-06-07 Adare Pharmaceuticals, Inc. Systèmes d'administration de médicament comprenant des solutions solides de médicaments faiblement basiques
CL2007003065A1 (es) 2006-10-24 2008-01-25 Wyeth Corp Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US8490764B2 (en) 2007-05-30 2013-07-23 Margaret Simester Portable storage and changing station
TW201242961A (en) 2007-06-20 2012-11-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
SG185276A1 (en) 2007-10-05 2012-11-29 Acucela Inc Alkoxy compounds for disease treatment
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
AU2009282076A1 (en) 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
KR20110086142A (ko) 2008-11-11 2011-07-27 노파르티스 아게 핑골리모드의 염
US20100240624A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
WO2010133672A1 (fr) 2009-05-20 2010-11-25 Clanotech Ab Dérivés d'acide quinoléine-3-carboxylique et leur utilisation médicale
MX2011013061A (es) 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas de fluticasona y metodos de uso.
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
WO2011008202A1 (fr) 2009-07-15 2011-01-20 Vanderbilt University Piégeurs d’isokétal et réduction des troubles impliquant une lésion oxydative
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
WO2011072141A1 (fr) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions et procédés pour le traitement de la dégénérescence maculaire
WO2011078204A1 (fr) 2009-12-24 2011-06-30 浜理薬品工業株式会社 Agent prophylactique ou thérapeutique destiné à une hyperlipémie et agent anti-fatigue
WO2011106729A2 (fr) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques.
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
JP2011203665A (ja) 2010-03-26 2011-10-13 Ophtecs Corp コンタクトレンズの白濁解消用製剤及び白濁解消方法
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
WO2012058695A2 (fr) 2010-10-29 2012-05-03 Najib Babul Compositions de (-)-17-(cyclobutylméthyl)morphinane-3,14-diol
WO2012097173A2 (fr) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Benzoazépines substituées utilisables comme modulateurs des récepteurs de type toll
US10463687B2 (en) 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
WO2012105887A1 (fr) 2011-01-31 2012-08-09 Tim Bowden Principe actif destiné à atténuer des troubles médicaux indésirables
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
WO2013056147A1 (fr) 2011-10-13 2013-04-18 Thomas Gadek Formulations topiques de peptides chémérine c15 pour le traitement d'états dermatologiques
WO2015187942A1 (fr) 2014-06-04 2015-12-10 Case Western Reserve University Compositions et méthodes de traitement de la rétinopathie diabétique
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US9817701B2 (en) 2011-12-12 2017-11-14 International Business Machines Corporation Threshold computing in a distributed computing system
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
MX367879B (es) 2012-08-01 2019-09-10 Lewis And Clark Pharmaceuticals Inc N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.
MX389676B (es) 2012-11-08 2025-03-20 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols
EP2948149A4 (fr) 2013-01-23 2016-12-14 Aldeyra Therapeutics Inc Maladies liées à un aldéhyde toxique et traitement
NZ709620A (en) 2013-01-23 2020-07-31 Semnur Pharmaceuticals Inc Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
SG11201505599YA (en) 2013-01-25 2015-08-28 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9713330B1 (en) 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
WO2015002893A1 (fr) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Élimination de lipides bioactifs de structures membranaires au moyen de cyclodextrines
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
CA2951284A1 (fr) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Creme transdermique
NO2721710T3 (fr) 2014-08-21 2018-03-31
EP3628640B1 (fr) 2014-09-02 2023-08-09 Hub Therapeutics Procédés de fabrication d'une molécule deutérée ou non-deutérée et formulations pharmaceutiques pour traitement
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders
US9953187B2 (en) 2014-11-25 2018-04-24 Honeywell International Inc. System and method of contextual adjustment of video fidelity to protect privacy
NZ735715A (en) 2015-04-15 2022-09-30 Beigene Ltd Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
KR20180073553A (ko) 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
WO2017147617A1 (fr) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Traitement des pathologies oculaires allergiques avec des cyclodextrines
MX2018013472A (es) 2016-05-09 2019-02-28 Aldeyra Therapeutics Inc Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
EP3463277A4 (fr) 2016-06-06 2020-01-01 GDD Therapeutics, LLC Formulations de 3-pyrrolidines substituées, compositions contenant celles-ci et leurs utilisations
AU2017317529A1 (en) 2016-08-22 2019-02-21 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
CN109640983A (zh) 2016-08-22 2019-04-16 奥尔德拉医疗公司 醛捕获化合物和其用途
MX2019003623A (es) 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EP3523283B1 (fr) 2016-10-05 2021-06-09 Mitobridge, Inc. Formes cristallines et salines de composés agonistes de ppar
US20180098937A1 (en) 2016-10-12 2018-04-12 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition
CN110431130A (zh) 2017-03-16 2019-11-08 奥尔德拉医疗公司 多晶型化合物和其用途
US10664688B2 (en) 2017-09-20 2020-05-26 Google Llc Systems and methods of detecting and responding to a visitor to a smart home environment
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
CN111527530B (zh) 2017-12-14 2022-06-21 路创技术有限责任公司 无线音频设备的隐私模式
WO2020018498A1 (fr) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Formulations de cyclodextrine
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
EP3833660A4 (fr) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. Composés polymorphes et leurs utilisations
US10915995B2 (en) 2018-09-24 2021-02-09 Movidius Ltd. Methods and apparatus to generate masked images based on selective privacy and/or location tracking
CN113056353B (zh) 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
WO2020072621A1 (fr) 2018-10-02 2020-04-09 Aldeyra Therapeutics, Inc. Solutions pour lentilles de contact et kits
JP2022511030A (ja) 2018-12-05 2022-01-28 アルデイラ セラピューティクス， インコーポレイテッド 注射可能な製剤
WO2020198064A1 (fr) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Formulations ophtalmiques et leurs utilisations
WO2020223717A1 (fr) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Procédé de préparation d'un piégeur d'aldéhyde et d'intermédiaires
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CA3149467A1 (fr) 2019-09-13 2021-03-18 Dean Eliott Formulations ophtalmiques de methotrexate
WO2021195211A1 (fr) 2020-03-24 2021-09-30 Aldeyra Therapeutics, Inc. Composés de quinoléine pour le traitement de troubles respiratoires et d'infections virales
US20230149383A1 (en) 2020-04-13 2023-05-18 Aldeyra Therapeutics, Inc. Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
WO2021231792A1 (fr) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Formulations pharmaceutiques et leurs utilisations
WO2021248031A1 (fr) 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Biomarqueurs de la sécheresse oculaire et leur utilisation pour le traitement
CN112541870A (zh) 2020-12-07 2021-03-23 北京大米科技有限公司 一种视频处理的方法、装置、可读存储介质和电子设备
US20220211691A1 (en) 2021-01-07 2022-07-07 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
WO2022150580A1 (fr) 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Traitement du syndrome de l'œil sec
CN112800947A (zh) 2021-01-27 2021-05-14 上海电气集团股份有限公司 视频监控方法、系统、电子设备及存储介质
IL309524A (en) 2021-07-02 2024-02-01 Aldeyra Therapeutics Inc Heterocyclic aldehyde trapping compounds and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2006127945A1 (fr) * 2005-05-26 2006-11-30 Neuron Systems Compositions et methodes de traitement de maladies retiniennes

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913722B2 (en) 2005-05-26 2021-02-09 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US9364471B2 (en) 2005-05-26 2016-06-14 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US11724987B2 (en) 2005-05-26 2023-08-15 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US12097188B2 (en) 2009-12-11 2024-09-24 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US12128013B2 (en) 2013-01-23 2024-10-29 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
WO2014116836A2 (fr) 2013-01-23 2014-07-31 Aldexa Therapeutics, Inc. Maladies liées à un aldéhyde toxique et traitement
US11701331B2 (en) 2013-01-23 2023-07-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN111135171B (zh) * 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US11771664B2 (en) 2013-01-23 2023-10-03 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10213395B2 (en) 2013-01-23 2019-02-26 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10543181B2 (en) 2013-01-23 2020-01-28 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10588874B2 (en) 2013-01-23 2020-03-17 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN111135171A (zh) * 2013-01-23 2020-05-12 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US11007157B2 (en) 2013-01-23 2021-05-18 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10111862B2 (en) * 2013-01-25 2018-10-30 Aldeyra Therapeutics, Inc. Traps in the treatment of macular degeneration
US20150344447A1 (en) * 2013-01-25 2015-12-03 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
US20190125729A1 (en) * 2013-01-25 2019-05-02 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
US12240816B2 (en) 2015-08-21 2025-03-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2017035077A1 (fr) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Composés deutérés et leurs utilisations
EP4400106A1 (fr) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Composés deutérés et leurs utilisations
US10426790B2 (en) 2016-02-28 2019-10-01 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3454858A4 (fr) * 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. Polythérapie de troubles et de maladies inflammatoires oculaires
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11583529B2 (en) 2017-10-10 2023-02-21 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US11312692B1 (en) 2018-08-06 2022-04-26 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP2022502499A (ja) * 2018-09-25 2022-01-11 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
EP3934660A4 (fr) * 2019-03-05 2022-11-23 Cornell University Compositions de matière présentant une activité pour éliminer la lipofuscine de cellules rétiniennes
EP3934660A1 (fr) 2019-03-05 2022-01-12 Cornell University Compositions de matière présentant une activité pour éliminer la lipofuscine de cellules rétiniennes
JP2022526917A (ja) * 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US12029735B2 (en) 2019-05-02 2024-07-09 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12064516B2 (en) 2020-05-13 2024-08-20 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2022092896A1 (fr) * 2020-10-29 2022-05-05 주식회사 피노바이오 Composition pharmaceutique destinée à être administrée comme collyre à un patient nécessitant une protection de nerf optique

Also Published As

Publication number Publication date
JP2016130266A (ja) 2016-07-21
JP2015057437A (ja) 2015-03-26
JP6063916B2 (ja) 2017-01-18
CA2782015A1 (fr) 2011-06-16
US20250144080A1 (en) 2025-05-08
US20180092882A1 (en) 2018-04-05
JP5885670B2 (ja) 2016-03-15
CA2782015C (fr) 2020-08-25
US20240148700A1 (en) 2024-05-09
JP2017052799A (ja) 2017-03-16
JP2013513612A (ja) 2013-04-22
US20120302601A1 (en) 2012-11-29
JP6378242B2 (ja) 2018-08-22
US12097188B2 (en) 2024-09-24
US9814701B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
US20250144080A1 (en) Compositions and methods for the treatment of macular degeneration
CN107362157B (zh) 用于医学和兽医学的眼科药物组合物
JP5315252B2 (ja) 眼科用薬物の輸送に有用なゲル
AU2020204384B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
US20050004074A1 (en) Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20110105450A1 (en) Ophthalmic formulations of fluticasone and methods of use
JP6888754B2 (ja) インサイチュでゲルを形成する医薬製剤
CN115869258A (zh) 用于治疗干眼病的调配物
JP2018531292A6 (ja) インサイチュでゲルを形成する医薬製剤
JPH08509205A (ja) β−シクロデキストリン誘導体及び治療剤を含んだ眼のための局所組成物
KR101396731B1 (ko) 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
EP2765988B9 (fr) Composition contenant bromofenac à l'administration à voie oculaire avec une biodisponibilité augmenté
KR20110042282A (ko) 눈 전면에 대한 지속 전달제로서의 인 시츄 겔화 시스템
Loftsson et al. Dexamethasone delivery to posterior segment of the eye
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
JP2019505587A (ja) ベタメタゾン経口スプレー製剤及び運動失調の治療への使用方法
WO2010137681A1 (fr) Agent prophylactique ou thérapeutique pour maladies rétiniennes comprenant du tranilast, méthode de prévention ou de traitement de maladies rétiniennes, tranilast ou sel pharmaceutiquement acceptable de celui-ci, et utilisation de ceux-ci
JPWO2006098292A1 (ja) 眼疾患治療剤
JP5087242B2 (ja) ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム
KR101587609B1 (ko) 베타-사이클로덱스트린을 포함하는 신규한 안약 제형
JPH02262518A (ja) 眼圧調整剤
CN115645420A (zh) 甘露糖及其药用衍生物在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用
IL311627A (en) Ophthalmic mixtures and their uses
CN121057724A (zh) 利用光反应性化合物治疗人类受试者视力丧失的方法
KR0159640B1 (ko) 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836694

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2782015

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012543284

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13514769

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10836694

Country of ref document: EP

Kind code of ref document: A1